CTLA4 and metastatic melanoma: The results were presented at ASCO 2021, and relatlimab was approved by the FDA as treatment for unresectable or metastatic melanoma on March 18, 2022, and were included in the PD-1/PD-L1 and anti-CTLA-4 antibody immunotherapy lineup (95).